Program
Pan-TEAD Inhibitor ODM-212
Its studies are led by Orion Corporation, Orion Pharma.
Furthest: phase 2, since Nov 29, 20241 company-led study, 1 open or runningNext primary completion: Dec 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Orion Corporation, Orion Pharma | 11 open or running | phase 2since Nov 29, 2024 | Nov 29, 2024 | Dec 31, 2027phase 2 · NCT06725758 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 29, 2024First study: phase 2 study in Solid TumoursFirst studyNCT06725758 · 315 planned · United States, Finland, France and more
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Solid TumoursNCT06725758
TargetBeta
“An orally bioavailable non-covalent small molecule inhibitor of the TEA domain (TEAD) family of transcription factors, including TEAD1, TEAD2, TEAD3 and TEAD4, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06725758Solid Tumours · United States, Finland, France and more | 2 | Recruiting | Dec 31, 2027 | 315 |
How it is read
Names in the registry
- “ODM-212”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.